[Federal Register Volume 84, Number 234 (Thursday, December 5, 2019)]
[Notices]
[Page 66685]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26278]



[[Page 66685]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Jenish Patel, Ph.D., 240-669-2894; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Broadly Protective Influenza Vaccine Comprising a Cocktail of 
Inactivated Avian Influenza Viruses

    Description of Technology: There is a great need for broadly 
protective, ``universal'' influenza virus vaccines given the antigenic 
drift and shift of influenza viruses and the variable protective 
efficacy of the current influenza vaccines. This technology relates to 
a broadly protective, ``universal'' influenza vaccine candidate 
composed of a cocktail of different low pathogenicity avian influenza 
virus subtypes inactivated by betapropiolactone (BPL). Vaccinating 
animals with BPL-inactivated whole virus vaccine comprising influenza 
virus strains belonging to four or more different low pathogenicity 
avian influenza hemagglutinin subtypes, intranasally or 
intramuscularly, provided extremely broad protection and heterosubtypic 
protection to lethal challenge with influenza viruses in both mice and 
ferrets. This influenza vaccine technology has a great potential to 
offer broad protection against both seasonal and pandemic-potential 
influenza viruses.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:

 Vaccine against viruses
 Vaccines against influenza virus
 Universal influenza virus vaccine

    Competitive Advantages:

 Broad protection to both seasonal and pandemic-potential 
influenza viruses
 Easy and cost-effective inactivation method
 Effective immune response due to the use of authentic viral 
antigens
 Animal data available

    Development Stage:

 In vivo (animal)

    Inventors: Jeffery K. Taubenberger, M.D., Ph.D., (NIAID) and Louis 
Merican Schwartzman, Ph.D. (NIAID).
    Publications: None.
    Intellectual Property: HHS Reference No. E-033-2018/0--PCT 
Application filed January 18, 2019--PCT/US2019/014220.
    Licensing Contact: To license this technology, please contact 
Jenish Patel, Ph.D., 240-669-2894; [email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is also seeking statements of 
capability or interest from parties interested in collaborative 
research. NIAID would like a prospective collaborator to have the 
capacity to generate clinical grade materials and perform clinical 
studies. NIAID will consider executing a Confidentiality Agreement with 
a prospective collaborator to facilitate receipt of a Capability 
Statement if requested. For collaboration opportunities, please contact 
Jenish Patel, Ph.D., 240-669-2894; [email protected].

    Dated: November 27, 2019.
Wade W. Green,
Acting Deputy Director, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-26278 Filed 12-4-19; 8:45 am]
 BILLING CODE 4140-01-P